BRAF in malignant melanoma progression and metastasis: potentials and challenges

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• BRAF mutations are prevalent in malignant melanomas, activating the MAPK pathway and promoting cell proliferation.
• BRAF mutations are linked to melanoma metastasis and altered expression of PTEN and ATG5.
• Targeted therapies have been developed to inhibit BRAF, offering personalized treatment strategies.

Purpose of the Study:

• To review the role of BRAF in melanoma progression and metastasis.
• To discuss current targeted therapies and their resistance mechanisms.
• To illustrate strategies for overcoming BRAF inhibitor resistance.

Main Methods:

• Literature review of recent advances in gene sequencing and melanoma research.
• Analysis of targeted therapy agents and immunotherapies.
• Examination of resistance mechanisms and combination treatment strategies.

Main Results:

• BRAF inhibitors (vemurafenib, dabrafenib, encorafenib) and immunotherapies (ipilimumab) are FDA-approved for melanoma treatment.
• Acquired resistance to BRAF inhibitors often involves MAPK pathway reactivation via CRAF/COT.
• Combination therapies, including BRAF/MEK inhibitors and BRAF/MEK inhibitors with immunotherapies, show promise in overcoming resistance.

Conclusions:

• BRAF plays a critical role in melanoma pathogenesis, proliferation, and metastasis.
• Resistance to BRAF inhibitors is a significant clinical challenge.
• Combination treatments represent a promising strategy to enhance efficacy and overcome resistance in melanoma therapy.